Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage

Neurobiology of Aging

Volumn 28, Issue 2, 2007, Pages 202-212

  Burbach, Guido J ^a   Vlachos, Andreas ^a   Ghebremedhin, Estifanos ^a   Turco, Domenico Del ^a   Coomaraswamy, Janaky ^b   Staufenbiel, Matthias ^c   Jucker, Mathias ^b,d   Deller, Thomas ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Alzheimer's disease; Anti A immunization; Anti A vaccination; APP transgenic mice; Electron microscopy; Intracerebral bleeding

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; FERRIC FERROCYANIDE; HEMOSIDERIN; IMMUNOGLOBULIN G2A ANTIBODY; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD VESSEL WALL; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; EVALUATION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MACROPHAGE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAMPLE SIZE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

EID: 33845426936     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.12.003     Document Type: Article

References (53)

1. Atwood C.S., Bowen R.L., Smith M.A., and Perry G. Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Res Brain Res Rev 43 (2003) 164-178
2. Atwood C.S., Perry G., and Smith M.A. Cerebral hemorrhage and amyloid-beta. Science 299 (2002) 1014
3. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7 (2001) 369-372
4. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 22 (2002) 7873-7878
5. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 100 (2003) 2023-2028
6. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 (2000) 916-919
7. Calhoun M.E., Burgermeister P., Phinney A.L., Stalder M., Tolnay M., Wiederhold K.H., et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 96 (1999) 14088-14093
8. Carson F.L. Histotechnology (1996), ASCP, Chicago
9. Castellani R.J., Smith M.A., Perry G., and Friedland R.P. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol Aging 25 (2004) 599-602
10. Das P., Howard V., Loosbrock N., Dickson D., Murphy M.P., and Golde T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 23 (2003) 8532-8538
11. Das P., Murphy M.P., Younkin L.H., Younkin S.G., and Golde T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22 (2001) 721-727
12. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98 (2001) 8850-8855
13. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., and Holtzman D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295 (2002) 2264-2267
14. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5 (2002) 452-457
15. Dodel R.C., Hampel H., and Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol 2 (2003) 215-220
16. Eng J.A., Frosch M.P., Choi K., Rebeck G.W., and Greenberg S.M. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 55 (2004) 250-256
17. Ferrer I., Boada R.M., Sanchez Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14 (2004) 11-20
18. Gelinas D.S., DaSilva K., Fenili D., George-Hyslop P., and McLaurin J. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 101 Suppl. 2 (2004) 14657-14662
19. Gomori G. Microtechnical demonstration of iron. Am J Pathol 12 (1936) 655-663
20. Grammas P., and Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging 22 (2001) 837-842
21. Greenberg S.M. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 51 (1998) 690-694
22. Herzig M.C., Winkler D.T., Burgermeister P., Pfeifer M., Kohler E., Schmidt S.D., et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 7 (2004) 954-960
23. Hoshi K., Yoshida K., Nakamura A., Tada T., Tamaoka A., and Ikeda S. Cessation of cerebral hemorrhage recurrence associated with corticosteroid treatment in a patient with cerebral amyloid angiopathy. Amyloid 7 (2000) 284-288
24. Jancar S., and Sanchez C.M. Immune complex-mediated tissue injury: a multistep paradigm. Trends Immunol 26 (2005) 48-55
25. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
26. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109 (2002) 813-836
27. Koller M.F., Mohajeri M.H., Huber M., Wollmer M.A., Roth Z'graggen B.V., Sandmeier E., et al. Active immunization of mice with an Abeta-Hsp70 vaccine. Neurodegen Dis 1 (2004) 20-28
28. Lemere C.A., Beierschmitt A., Iglesias M., Spooner E.T., Bloom J.K., Leverone J.F., et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165 (2004) 283-297
29. Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Desai R., et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann NY Acad Sci 920 (2000) 328-331
30. Lemere C.A., Spooner E.T., LaFrancois J., Malester B., Mori C., Leverone J.F., et al. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 14 (2003) 10-18
31. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8 (2002) 1263-1269
32. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
33. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 (2003) 448-452
34. Oh U., Gupta R., Krakauer J.W., Khandji A.G., Chin S.S., and Elkind M.S. Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology 62 (2004) 494-497
35. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
36. Paganetti P.A., Lis M., Klafki H.W., and Staufenbiel M. Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid. J Neurosci Res 46 (1996) 283-293
37. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 (2002) 1379
38. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid {beta}. J Neurosci 25 (2005) 629-636
39. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3 (2002) 824-828
40. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
41. Spooner E.T., Desai R.V., Mori C., Leverone J.F., and Lemere C.A. The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol. Vaccine 21 (2002) 290-297
42. Stalder M., Deller T., Staufenbiel M., and Jucker M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging 22 (2001) 427-434
43. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94 (1997) 13287-13292
44. Vinters H.V. Cerebral amyloid angiopathy. A critical review. Stroke 18 (1987) 311-324
45. Walker L.C. Animal models of cerebral beta-amyloid angiopathy. Brain Res Brain Res Rev 25 (1997) 70-84
46. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48 (2000) 567-579
47. Weller R.O., Massey A., Newman T.A., Hutchings M., Kuo Y.M., and Roher A.E. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 153 (1998) 725-733
48. Wilcock D.M., Gordon M.N., Ugen K.E., Gottschall P.E., DiCarlo G., Dickey C., et al. Number of Abeta inoculations in APP + PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol 20 (2001) 731-736
49. Wilcock D.M., Rojiani A., Rosenthal A., Levkowitz G., Subbarao S., Alamed J., et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24 (2004) 6144-6151
50. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflamm 1 (2004) 24
51. Winkler D.T., Biedermann L., Tolnay M., Allegrini P.R., Staufenbiel M., Wiessner C., et al. Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. Ann Neurol 51 (2002) 790-793
52. Winkler D.T., Bondolfi L., Herzig M.C., Jann L., Calhoun M.E., Wiederhold K.H., et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21 (2001) 1619-1627
53. Zhang J., Wu X., Qin C., Qi J., Ma S., Zhang H., et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14 (2003) 365-379